Sun Pharma Advanced Research Company Ltd (SPARC) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 532872 | NSE: SPARC | Business Support | Small Cap

Sun Pharma Adv. Res Share Price

152.05 0.10 0.07%
as on 05-Dec'25 11:34

Sun Pharma Advanced Research Company Ltd (SPARC) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 532872 | NSE: SPARC | Business Support | Small Cap

DeciZen - make an informed investing decision on Sun Pharma Adv. Res

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Sun Pharma Advanced Research Company stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
4,931.1 Cr.
52-wk low:
109.2
52-wk high:
241

Is Sun Pharma Advanced Research Company Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Sun Pharma Adv. Res: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Sun Pharma Advanced Research Company Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % -71.4%-94.7%-113.1%-60%-179%-254.1%-225.6%-69.4%-112.9%-321.2%-
Value Creation
Index
-6.3-8.0-9.4-5.3NANANA-6.1-9.4NA-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 16118178.318376.825313723975.671.860
Sales YoY Gr.-12.2%-56.8%133.7%-58%229.3%-45.7%74%-68.4%-5%-
Adj EPS -3-4.9-9.3-5.5-12-5.9-7.6-6.9-12-10.6-8.3
YoY Gr.-NANANANANANANANANA-
BVPS (₹) 1.26.43.711.3-0.7-6.4-7.515.83.9-6.8-10.7
Adj Net
Profit
-69.8-120-234-144-314-154-207-223-389-345-269
Cash Flow from Ops. -44.2-128-183-172-211-152-208-69.1-429-362-
Debt/CF from Ops. -1.3-0-0-0-0.3-1.5-0.4-0-0.1-0.7-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -8.6%-1.4%-19.4%-5%
Adj EPS NANANANA
BVPS-221.1%NANA-276.6%
Share Price -8.3% -4.6% -15.2% -29.8%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
-106.1-126.7-136.6-60-226164.6301.5-81.8-121.972094.4
Op. Profit
Mgn %
-39-67.7-310-79.1-397.7-53.4-135.5-88.7-530.7-453.6-413.6
Net Profit
Mgn %
-43.3-66.5-299.2-78.9-408.3-60.8-150.5-93.2-514.5-480.4-450.8
Debt to
Equity
1.9000-3.6-1.4-0.400.4-1.2-
Working Cap
Days
1632106412545541753513391,15491860
Cash Conv.
Cycle
-130-170-113-272-254-119-60-85-79-126-1,662

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Sun Pharma Advanced Research Company Ltd.

Standalone Consolidated
TTM EPS (₹) -8.3 -8.2
TTM Sales (₹ Cr.) 59.6 59.6
BVPS (₹.) -10.7 -10.6
Reserves (₹ Cr.) -381 -377
P/BV -14.14 -14.31
PE 0.00 0.00
From the Market
52 Week Low / High (₹) 109.20 / 240.95
All Time Low / High (₹) 38.44 / 593.93
Market Cap (₹ Cr.) 4,931
Equity (₹ Cr.) 32.5
Face Value (₹) 1
Industry PE 38.7

Management X-Ray of Sun Pharma Adv. Res:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *2.782.782.782.782.782.780.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Sun Pharma Adv. Res - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Sun Pharma Adv. Res

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales16118178183772531372397672
Operating Expenses 224304321334387388324453479399
Manufacturing Costs3134372336214139186146121
Material Costs0000000000
Employee Cost 578410181939298107119109
Other Costs 1371851832302588287160214169
Operating Profit -63-123-243-151-310-135-187-214-404-327
Operating Profit Margin (%) -39.2%-67.8%-310.0%-82.7%-403.0%-53.4%-136.0%-89.6%-534.0%-456.0%
Other Income 314514105711292
Interest 220031113829
Depreciation 888891110121211
Exceptional Items 00490000000
Profit Before Tax -70-119-197-145-312-151-203-223-388-345
Tax 0000000000
Profit After Tax -70-119-197-145-312-151-203-223-388-345
PAT Margin (%) -43.4%-65.8%-251.0%-79.5%-406.0%-59.7%-148.0%-93.2%-513.0%-481.0%
Adjusted EPS (₹)-3.0-4.8-7.9-5.6-11.9-5.8-7.5-6.9-12.0-10.6
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 3015893296-19-168-203513125-221
Share Capital 24252526262627323232
Reserves 613368270-45-194-23048092-253
Minority Interest0000000000
Debt55321661930047258
Long Term Debt32216113000100
Short Term Debt5200060800047158
Trade Payables5894102831599172148150124
Others Liabilities 23211161866114411169165167
Total Liabilities 167277313398273230280830486329

Fixed Assets

Gross Block107776780136123133146152153
Accumulated Depreciation3781523323241404957
Net Fixed Assets 70695258104919210610395
CWIP 1132432526274454
Investments 010108211861229120
Inventories0000000000
Trade Receivables9391810161828331616
Cash Equivalents flag 1370110911121551
Others Assets 748713195112101121262167162
Total Assets 167277313398273230280830486329

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity -44-128-183-172-211-152-208-69-429-362
PBT -70-119-246-145-312-151-203-223-388-345
Adjustment 9-14-22949177-1119
Changes in Working Capital 301320-0102-48-26141-26-47
Tax Paid -14-21-10-5-10-255-411
Cash Flow From Investing Activity -13-7-105-1021552-29-548391158
Capex -12-8-18-13-54-1-25-15-26-10
Net Investments -0-9-88-932093-5-535395153
Others -1111300022215
Cash Flow From Financing Activity 511942242745515922961743201
Net Proceeds from Shares 2250133367-00167000
Net Proceeds from Borrowing -1-10-10106-11300100
Interest Paid -2-3-0-0-2-8-14-8-2-8
Dividend Paid 0000000000
Others 51-5291-92576118962544109
Net Cash Flow -760-63009-8-14-4

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)-109.16-127.4-156.84-74.72N/AN/AN/A-143.72-121.73N/A
ROCE (%)-71.37-94.66-113.05-59.95N/AN/AN/A-69.44-112.88N/A
Asset Turnover Ratio1.030.820.270.510.231.010.540.430.110.18
PAT to CFO Conversion(x)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Working Capital Days
Receivable Days3348132286224604611780
Inventory Days0000000000
Payable Days0000000000

Sun Pharma Advanced Research Company Ltd Stock News

Sun Pharma Advanced Research Company Ltd FAQs

The current trading price of Sun Pharma Adv. Res on 05-Dec-2025 11:34 is ₹152.1.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Sun Pharma Adv. Res stood at ₹4,931.1.
The latest P/E ratio of Sun Pharma Adv. Res as of 04-Dec-2025 is 0.00.
The latest P/B ratio of Sun Pharma Adv. Res as of 04-Dec-2025 is -14.14.
The 52-week high of Sun Pharma Adv. Res is ₹240.9 and the 52-week low is ₹109.2.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sun Pharma Adv. Res is ₹59.60 ( Cr.) .

About Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company (SPARC) is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery. SPARC was formed in 2007 through a demerger from SUN PHARMA, a global leader in speciality generics. It strive to build an enduring innovation engine built on strong scientific execution, high value analytics and aggressive portfolio management. A robust mix of internal ideation and strategic partnering with academic innovators and bio-pharma entrepreneurs fuel engine with potentially high impact ideas.

The company partner with thought-leading clinicians across the world for ideas and access. Innovation through integration of partner knowledge and efficient internal execution shapes future. SPARC is a vibrant innovation community spread over three locations globally. It endeavour to develop a meritocracy which takes pride in continuous learning and re-invention. SPARC is a responsible public company committed to maintaining highest standards of ethics and transparency.

Business area of the company

The company is engaged in the pharmaceutical research and development. The company’s core focus is innovation and new product development for global markets. SPARC undertakes projects in research and technology for new chemical entities (NCE’s) or new molecules, and novel drug delivery systems (NDDS).

Products

  • Therapeutic Focus (Oncology, Neuro Degeneration, Ophthalmology, Dermatology)
  • Delivery Technologies (Gastro Retentive Innovative Device, Wrap Matrix, Abuse Deterrent Program, Nanotecton Technology, Dry Powder Inhalation, TearAct, Lipixelle, Gel Free Reservoir)
  • Research Programs (Taclantis, SCO - 088, SCD - 044, SCC - 138, SCO - 120)

Milestones

  • 2006: SPARC is founded in Vadodara, India
  • 2007: Innovative R&D business was demerged from Sun Pharmaceutical Industries Limited to focus on innovative drug research
  • 2007: Listed on Bombay Stock Exchange and National Stock Exchange of India
  • 2012: 1st NDA filed with USFDA for Elepsia XR
  • 2012: Raised Rs. 200 crore through Rights Issue
  • 2013: Filed NDA for Xelpros with USFDA
  • 2014: US rights for Xelpros licensed to a subsidiary of Sun Pharma
  • 2015: Entered into research collaboration in the field of Oncology with US University
  • 2015: Launched Bevetex (PICS) in India
  • 2016: Raised Rs. 250 crore through Rights Issue
  • 2017: Secured funding of up to Rs. 500 crore through Preferential Allotment of warrants convertible into equity shares
  • 2018: Entered into collaboration with Schrödinger to accelerate Neurodegeneration Drug Development Programs
  • 2018: Positive top line results reported for the pivotal bioequivalence study of Taclantis (Paclitaxel Injection Concentrate for Suspension)
  • 2018: US FDA approved Xelpros for the treatment of open-angle glaucoma or ocular hypertension
  • 2019: Entered into licensing agreement with Bioprojet SCR to acquire exclusive rights for Investigational Medicinal Product, SCD-044
  • 2019: Entered into a licensing deal with China Medical System Holdings Limited (CMS) to develop and commercialize multiple products in Mainland China, Hong Kong, Macao, and Taiwan
  • 2019: Orphan Drug Designation received from the US FDA for SPARCs neonatal seizures drug, Phenobarbital
  • 2019: Orphan Drug Designation received from the US FDA for SPARCs Chronic Myeloid Leukemia drug, SCO-088
  • 2019: NDA for Taclantis (Paclitaxel Injection Concentrate for Suspension) accepted by US FDA for review
  • 2019: Entered into collaboration with HitGen for Innovative Drug Discovery Research
  • 2020: Entered into a worldwide license agreement for SCD-044 with Sun Pharma
  • 2020: Entered into collaboration with the University of Michigan to kickstart research and development of potential new medications
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×